Study on acupuncture and moxibustion improving endometrial receptivity of patients with endometrial atypical hyperplasia and endometrial cancer after fertility preserving therapy (1)

Research and development of new technology and new scheme for preserving fertility of gynecological tumor

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100042612

Enrollment

Unknown

Registered

2021-01-24

Start date

2021-01-25

Completion date

Unknown

Last updated

2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Cancer and Endometrial Atypical Hyperplasia

Interventions

Case series:acupuncture and Moxibustion after fertility preservation

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Aged <= 40 years, have strong desire to have children; (2) atypical hyperplasia of uterus, endometrial cancer progesterone treatment remission; (3) endometrial cancer iag1-iag2 stage, endometrial atypical hyperplasia; (4) imaging examination confirmed that the tumor was confined to the endometrium; (5) estrogen and progesterone receptor (ER, PR) were positive; (6) peripheral blood CA125 the results showed normal; (7) no contraindication of progesterone treatment; (8) evaluation of reproductive function before treatment, no other factors of fertility disorders; (9) acupuncture treatment to improve endometrial receptivity after retaining reproductive function; (10) signing informed consent and good follow-up conditions.

Exclusion criteria

Exclusion criteria: (1) Patients with severe medical diseases and severe impairment of liver and kidney function; (2) patients with endometrioid adenocarcinoma whose pathological stage or grade is higher than stage IA G1, or with deep myometrial invasion, cervical invasion or distant metastasis in pelvic and abdominal cavity; (3) patients with drug allergy and contraindications; (4) patients with other types of endometrial cancer or other malignant tumors of reproductive system; patients with breast cancer or other malignant tumors He can not use progesterone hormone dependent tumor patients; (5) require hysterectomy or other methods in addition to conservative treatment; (6) deep vein thrombosis, stroke, myocardial infarction.

Design outcomes

Primary

Measure	Time frame
Endometrial thickness;	—

Secondary

Measure	Time frame
Live birth rate;Endometrial morphology;Endometrial blood flow;Endometrial peristalsis;Clinical pregnancy rate;Early spontaneous abortion rate;Preterm birth rate;Incidence rate of complications during pregnancy;Egg rate;Available embryo rate;High quality embryo rate;Embryo implantation rate;Recurrence rate;Relapse free survival;Pittsburgh sleep quality index;Anxiety and depression assessment;	—

Countries

China

Contacts

Public ContactQun Lu

Peking University People's Hospital

luqun1023@sina.com+86 13164242297

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026